References
- Aldenkamp, A. P., Baker, G., Mulder, O. G., Chadwick, D., Cooper, P., Doelman, J., Duncan, R., Gassmann-Mayer, C., De Haan, G. J., Hughson, C., Hulsman, J., Overweg, J., Pledger, G., Rentmeester, T. W., Riaz, H., & Wroe, S. (2000). A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia, 41(9), 1167–1178. https://doi.org/https://doi.org/10.1111/j.1528-1157.2000.tb00322.x
- Bangash, A., & Bharmal, Q. (2021). A dementia‐like picture: Could it be the medication? Progress in Neurology and Psychiatry, 25(3), 21–24. https://doi.org/https://doi.org/10.1002/pnp.716
- Burton, L. A., and Harden, C. (1997). Effect of topiramate on attention. Epilepsy Research, 27(1), 29–32. https://doi.org/https://doi.org/10.1016/s0920-1211(96)01015-7
- Chiossi, L., Negro, A., Capi, M., Lionetto, L., & Martelletti, P. (2014). Sodium channel antagonists for the treatment of migraine. Expert Opinion on Pharmacotherapy, 15(12), 1697–1706. https://doi.org/https://doi.org/10.1517/14656566.2014.929665
- Eddy, C. M., Rickards, H. E., & Cavanna, A. E. (2011). The cognitive impact of antiepileptic drugs. Therapeutic Advances in Neurological Disorders, 4(6), 385–407. https://doi.org/https://doi.org/10.1177/1756285611417920
- Fritz, N., Glogau, S., Hoffmann, J., Rademacher, M., Elger, C. E., & Helmstaedter, C. (2005). Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy & Behavior, 6(3), 373–381. https://doi.org/https://doi.org/10.1016/j.yebeh.2005.01.002
- Gomer, B., Wagner, K., Frings, L., Saar, J., Carius, A., Härle, M., Steinhoff, B. J., & Schulze-Bonhage, A. (2007). The influence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate. Epilepsy and Behavior, 10(3), 486–494. https://doi.org/https://doi.org/10.1016/j.yebeh.2007.02.007
- Huppertz, H. J., Quiske, A., & Schulze-Bonhage, A. (2001). Kognitive Beeinträchtigungen unter add-on-Therapie mit Topiramat. Der Nervenarzt, 72(4), 275–280. https://doi.org/https://doi.org/10.1007/s001150050750
- Jansen, J. F. A., Aldenkamp, A. P., Marian Majoie, H. J., Reijs, R. P., de Krom, M. C. T. F. M., Hofman, P. A. M., Eline Kooi, M., Nicolay, K., & Backes, W. H. (2006). Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. Epilepsy and Behavior, 9(1), 181–185. https://doi.org/https://doi.org/10.1016/j.yebeh.2006.05.004
- Javed, A., Cohen, B., Detyniecki, K., Hirsch, L. J., Legge, A., Chen, B., Bazil, C., Kato, K., Buchsbaum, R., & Choi, H. (2015). Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: An extended follow-up. Seizure, 29, 34–40. https://doi.org/https://doi.org/10.1016/j.seizure.2015.03.013
- Kockelmann, E., Elger, C. E., & Helmstaedter, C. (2003). Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of Topiramate in epilepsy patients. Epilepsy Research, 54(2–3), 171–178. https://doi.org/https://doi.org/10.1016/S0920-1211(03)00078-0
- Kockelmann, E., Elger, C. E., & Helmstaedter, C. (2004). Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: Relationships to blood serum levels and comedication. Epilepsy & Behavior, 5(5), 716–721. https://doi.org/https://doi.org/10.1016/j.yebeh.2004.06.017
- Lee, H. W., Jung, D. K., Suh, C. K., Kwon, S. H., & Park, S. P. (2006). Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up. Epilepsy and Behavior, 8(4), 736–741. https://doi.org/https://doi.org/10.1016/j.yebeh.2006.03.006
- Loring, D. W., Marino, S., & Meador, K. J. (2007). Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychology Review, 17(4), 413–425. https://doi.org/https://doi.org/10.1007/s11065-007-9043-9
- Loring, D. W., Williamson, D. J., Meador, K. J., Wiegand, F., & Hulihan, J. (2011). Topiramate dose effects on cognition: A randomized double-blind study. Neurology, 76(2), 131–137. https://doi.org/https://doi.org/10.1212/WNL.0b013e318206ca02
- Lyseng-Williamson, K. A., & Yang, L. P. H. (2007). Topiramate: A review of its use in the treatment of epilepsy. Drugs, 67(15), 2231–2256. https://doi.org/https://doi.org/10.2165/00003495-200767150-00008
- Macone, A. E., & Perloff, M. D. (2017). Triptans and migraine: Advances in use, administration, formulation, and development. Expert Opinion on Pharmacotherapy, 18(4), 387–397. https://doi.org/https://doi.org/10.1080/14656566.2017.1288721
- Martin, R., Kuzniecky, R., Ho, S., Hetherington, H., Pan, J., Sinclair, K., Gilliam, F., & Faught, E. (1999). Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology, 52(2), 321–327. https://doi.org/https://doi.org/10.1212/WNL.52.2.321
- Meador, K. J., Loring, D. W., Hulihan, J. F., Kamin, M., & Karim, R. (2003). Differential cognitive and behavioral effects of topiramate and valproate. Neurology, 60(9), 1483–1488. https://doi.org/https://doi.org/10.1212/01.WNL.0000063308.22506.19
- Meador, K. J., & Loring, D. W. (2016). Developmental effects of antiepileptic drugs and the need for improved regulations. Neurology, 86(3), 297–306. https://doi.org/https://doi.org/10.1212/WNL.0000000000002119
- Meschede, C., Witt, J. A., Brömling, S., Moskau-Hartmann, S., Rademacher, M., Surges, R., Von Wrede, R., & Helmstaedter, C. (2020). Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: A retrospective study using Bayes statistics. Epilepsia, 61(7), 1481–1490. https://doi.org/https://doi.org/10.1111/epi.16576
- Romigi, A., Cervellino, A., Marciani, M. G., Izzi, F., Massoud, R., Corona, M., Torelli, F., Zannino, S., Uasone, E., & Placidi, F. (2008). Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: An open study. European Journal of Neurology, 15(2), 190–195. https://doi.org/https://doi.org/10.1111/j.1468-1331.2007.02033.x
- Rorsman, I., & Källen, K. (2001). Recovery of cognitive and emotional functioning following withdrawal of topiramate maintenance therapy. Seizure, 10(8), 592–595. https://doi.org/https://doi.org/10.1053/seiz.2001.0554
- Salinsky, M. C., Storzbach, D., Spencer, D. C., Oken, B. S., Landry, T., & Dodrill, C. B. (2005). Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology, 64(5), 792–798. https://doi.org/https://doi.org/10.1212/01.WNL.0000152877.08088.87
- Silberstein, S., Diener, H. C., Lipton, R., Goadsby, P., Dodick, D., Bussone, G., Freitag, F., Schwalen, S., Ascher, S., Morein, J., Greenberg, S., Biondi, D., & Hulihan, J. (2008). Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate. Headache, 48(7), 1087–1095. https://doi.org/https://doi.org/10.1111/j.1526-4610.2008.01185.x
- Thompson, P. J., Baxendale, S. A., Duncan, J. S., & Sander, J. W. A. S. (2000). Effects of topiramate on cognitive function. Journal of Neurology Neurosurgery and Psychiatry, 69(5), 636–641. https://doi.org/https://doi.org/10.1136/jnnp.69.5.636
- Witt, J.-A., Elger, C. E., & Helmstaedter, C. (2013a). Which drug-induced side effects would be tolerated in the prospect of seizure control? Epilepsy & Behavior, 29(1), 141–143. https://doi.org/https://doi.org/10.1016/j.yebeh.2013.07.013
- Witt, J.-A., Elger, C. E., & Helmstaedter, C. (2013b). Impaired verbal fluency under topiramate–evidence for synergistic negative effects of epilepsy, topiramate, and polytherapy. European Journal of Neurology , 20(1), 130–137. https://doi.org/https://doi.org/10.1111/j.1468-1331.2012.03814.x
- Witt, J.-A., Elger, C. E., & Helmstaedter, C. (2015). Adverse cognitive effects of antiepileptic pharmacotherapy: Each additional drug matters. European Neuropsychopharmacology, 25(11), 1954–1959. https://doi.org/https://doi.org/10.1016/j.euroneuro.2015.07.027
- Witt, J.-A., & Helmstaedter, C. (2012). Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients. Journal of Neurology, 259(8), 1727–1731. https://doi.org/https://doi.org/10.1007/s00415-012-6526-2
- Witt, J.-A., & Helmstaedter, C. (2013). Monitoring the cognitive effects of antiepileptic pharmacotherapy — Approaching the individual patient. Epilepsy & Behavior, 26(3), 450–456. https://doi.org/https://doi.org/10.1016/j.yebeh.2012.09.015
- Witt, J.-A., & Helmstaedter, C. (2017). How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opinion on Pharmacotherapy, 18(6), 1–4. https://doi.org/https://doi.org/10.1080/14656566.2017.1309025